Main menu button

Alzinova AB

Alzinova is developing a vaccine against the group of substances that are thought to cause Alzheimer’s disease (so-called oligomers consisting of amyloid-beta-42). The vaccine, ALZ-101, is now tested in the clinical phase. The goal is to then find a partner.

Homepage: www.alzinova.com
Research: September 17, 2020 (SE)
Industry: Biotech
Exchange: First North Growth Market
Ticker: ALZ:SS
Markus Augustsson
Markus Augustsson LinkedIn
Head of Equity Research
+46 76 235 03 20

Nyheter

September 17, 2020 Research report: Unique Alzheimer’s vaccine with potential in the billions (Swedish)

Other Researches

Abera Bioscience Healthcare
Kancera AB Healthcare
DanCann Pharma A/S Healthcare
InCoax Networks AB Healthcare, Technology
FRISQ Holding AB Healthcare
GHP Specialty Care AB Healthcare
Nedynamics Healthcare
Elicera Therapeutics AB Healthcare